You are here

Humira

Meet the Top Ten Drugs of 2024 (Maybe)

Meet the Top Ten Drugs of 2024 (Maybe)

Drug Channels

Bristol-Myers Squibb

Flag link:

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Pharmaforum

psoriatic arthritis

Flag link:

Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar

Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar

Fierce Pharma

CinnaGen Pharmaceuticals

Flag link:

Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose

Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose

Fierce Pharma

rheumatoid arthritis

Flag link:

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

Fierce Pharma

Flag link:

AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.

AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.

Marketwatch

Boehringer Ingelheim

Flag link:

Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline

Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline

Marketwatch

Flag link:

Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun

Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun

Fierce Pharma

Flag link:

What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

Motley Fool

Flag link:

AbbVie successor to Humira in psoriasis gains FDA approval

AbbVie successor to Humira in psoriasis gains FDA approval

BioCentury

Flag link:

AbbVie shareholder joins the growing ranks of critics, calling for an independent chairman

AbbVie shareholder joins the growing ranks of critics, calling for an independent chairman

Endpoints

Richard Gonzalez

Flag link:

AbbVie's massive Humira discounts are stifling Netherlands biosimilars: report

AbbVie's massive Humira discounts are stifling Netherlands biosimilars: report

Fierce Pharma

Flag link:

AbbVie faces class action lawsuit from New York grocery union over Humira 'patent thicket'

AbbVie faces class action lawsuit from New York grocery union over Humira 'patent thicket'

Fierce Pharma

Flag link:

2 Things Investors Are Missing About AbbVie

2 Things Investors Are Missing About AbbVie

Motley Fool

Flag link:

AbbVie’s Humira Remains the Top-Selling Prescription for 2018

AbbVie’s Humira Remains the Top-Selling Prescription for 2018

Biopharma Dive

prescription data

Flag link:

Takeda’s Entyvio Bests Humira in Head-to-Head UC Study

Takeda’s Entyvio Bests Humira in Head-to-Head UC Study

BioSpace

ulcerative colitis

Flag link:

AbbVie and Pfizer return to the top of pharma's TV spending list for February

AbbVie and Pfizer return to the top of pharma's TV spending list for February

Fierce Pharma

Flag link:

Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight

Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight

Fierce Pharma

Boehringer Ingelheim

Flag link:

Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress

Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress

Forbes

pharma executives

Flag link:

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

Pharmaforum

priority review

rheumatoid arthritis

Flag link:

Pages